$2.5 Million Department of Defense Grant Funds Development of Targeted Therapy for Triple-Negative Breast Cancer
Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the…
Read the full articleYou might also wanna read
Weill Cornell Medicine receives DoD grant to target triple-negative breast cancer
Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer si
Anticancer 'nanoswitch' technology shows promise in animal model of triple-negative breast cancer, colorectal cancer
A research team led by Professor Yoosoo Yang (Department of Integrative Biotechnology) of Sungkyunkwan University, in collaboration with the
CMU-Q Researchers Discover Genetic Molecule That May Suppress Breast Cancer Tumors
Researchers at Carnegie Mellon University in Qatar (CMU-Q) have discovered a genetic molecule that could provide new approaches to treating
cmu.edu·3d agoTurning Off Cancer-Promoting Signals, Turning On Attack Signals. Anticancer "Nanoswitch" Technology Developed
Complete tumor remission and suppression of recurrence/metastasis demonstrated in animal models of triple-negative breast cancer and colorec
Experimental drug shows promise against NRAS-driven melanoma
A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a groundbreaking pathway-targeted therapy coul
Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes
Clonal hematopoiesis (CH) is the age-related expansion of mutated hematopoietic stem cells without hematologic abnormalities. In patients wi
Comments
Sign in to join the conversation.
No comments yet. Be the first.